Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mirum Pharmaceuticals ( (MIRM) ) just unveiled an announcement.
On May 15, 2026, Mirum Pharmaceuticals issued $690 million of 0.00% Convertible Senior Notes due 2032 in a Rule 144A private placement, with the securities structured as senior unsecured obligations carrying no regular interest and featuring multiple conversion, redemption and repurchase triggers tied to Mirum’s share price and corporate events. The company expects net proceeds of about $671.6 million, of which roughly $475 million plus 3.22 million shares will be used to exchange $237.2 million of its 4.00% Convertible Senior Notes due 2029, with the balance earmarked for general corporate purposes including potential acquisitions, reshaping Mirum’s capital structure and potentially diluting existing shareholders over time.
The notes may be converted into cash, stock or a mix at Mirum’s option at an initial rate implying a conversion price of about $138.94 per share, with anti-dilution and make-whole adjustments designed to protect noteholders in certain transactions or redemptions. The issuance, sold only to qualified institutional buyers and unregistered under the Securities Act, introduces a complex set of default, redemption and fundamental change provisions that give creditors significant protections while providing Mirum with long-dated, interest-free financing to support its rare disease growth strategy.
The most recent analyst rating on (MIRM) stock is a Buy with a $154.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.
Spark’s Take on MIRM Stock
According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.
The score is held back primarily by weak current financial quality—large losses and a return to TTM cash burn—despite strong revenue growth and attractive gross margins. Offsetting this, technicals are strong (price above key moving averages with positive momentum) and the latest call/events were constructive with raised 2026 sales guidance and positive clinical catalysts, but valuation support remains limited due to ongoing unprofitability and no dividend.
To see Spark’s full report on MIRM stock, click here.
More about Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a rare disease-focused biopharmaceutical company with a global commercial footprint in rare liver and genetic disorders. Its marketed portfolio includes LIVMARLI for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM for bile-acid synthesis disorders and CTEXLI for cerebrotendinous xanthomatosis, supported by a late-stage pipeline targeting cholestatic, viral and genetic conditions.
Average Trading Volume: 996,143
Technical Sentiment Signal: Buy
Current Market Cap: $6.23B
Learn more about MIRM stock on TipRanks’ Stock Analysis page.